User:ADACAP/sandbox

= Oxodotreotide = Oxodotreotide, or dotatate, is a ligand-linked somatostatin peptide analog also known as DOTA0, Tyr3]-octreotate. The peptide was invented by Jack Erion, and Ananth Srinivasan in the mid-90’s. Oxodotreotide is closely related to the peptide, edotreotide, in that both molecules are identical, except at the C-termus, where edotreotide contains a threoninol residue, and oxodotreotide contains L-threonine. Currently, the oxodotreotide name is only used in context with the radiopharmaceutical, lutetium (177Lu) oxodotreotide, which is the international nonproprietary name (INN) assigned by WHO. Another radiopharmaceutical with the INN, gallium (68Ga) dotatate, is composed of the same chemical entity as lutetium (177Lu) oxodotreotide, (DOTA0, Tyr3]-Octreotate, except that the DOTA moiety of one molecule is complexed with the radionuclide, lutetium-177, and the other is complexed with gallium-68. The gallium-68 radiolabeled peptide is used as a diagnostic PET imaging agent in patients with neuroendocrine tumors, and the lutetium-177 radiolabeled peptide is used as a therapeutic agent in patients with neuroendocrine tumors. Both products have been developed by Advanced Accelerator Applications. Gallium (68Ga) dotatate is approved for use in the United States for the diagnosis of neuroendocrine tumors and is marketed under the brand name, NETSPOT®. Lutetium (177Lu) oxodotreotide has marketing approval in the EU, and is currently under review by the FDA. The brand name for the product is Lutathera®.